Antimüllerian hormone and F2-isoprostanes in the Coronary Artery Risk Development in Young Adults (CARDIA) Study

Catherine Kim, James C. Slaughter, James G. Terry, David R. Jacobs, Nisha Parikh, Duke Appiah, Benjamin Leader, Molly B. Moravek, Melissa F. Wellons

Research output: Contribution to journalArticlepeer-review

6 Scopus citations


Objective: To examine whether F2-isoprostanes, a marker of systematic oxidative stress, are associated with antimüllerian hormone (AMH), an indicator of ovarian reserve, in a population-based cohort of women of black and white ethnicities. Design: Cross-sectional analysis. Setting: Not applicable. Patients: The CARDIA Women's Study, a population-based cohort. Black (n = 398) and white (n = 432) late reproductive−aged women (mean age 40 ± 3.6 years) without histories of gynecologic surgery. Main Outcome Measures: Log-transformed serum AMH concentrations. Results: Linear regression models evaluated whether plasma F2-isoprostanes were associated with log-transformed AMH after adjustment for age, race, smoking, body mass index, and oral contraceptive pill use. Higher levels of F2-isoprostanes were associated with lower AMH levels (β −0.048 per standard deviation, 95% confidence interval −0.087, −0.01). The observed associations were stronger at younger ages (P=.04 for interaction between levels of age and F2-isoprostanes). Indicators of other steps in the oxidative stress pathway (superoxide dismutase, paraoxonase activity, oxidized low-density lipoprotein cholesterol, and carotenoids) were not associated with AMH, although lower phospholipase A2 activity (β 0.036 per standard deviation, 95% confidence interval 0.001, 0.071) was associated with lower AMH across all ages. Conclusion: In a population-based cohort, higher levels of F2-isoprostanes were associated with lower ovarian reserve, particularly at younger ages.

Original languageEnglish (US)
Pages (from-to)646-652
Number of pages7
JournalFertility and Sterility
Issue number3
StatePublished - Sep 2020

Bibliographical note

Funding Information:
C.K. has nothing to disclose. J.C.S. has nothing to disclose. J.G.T. has nothing to disclose. D.R.J., Jr. has nothing to disclose. N.P. has nothing to disclose. D.A. has nothing to disclose. B.L. reports grant from Vanderbilt University during the submitted work, and personal fees from ReproSource outside the submitted work. M.B.M. has nothing to disclose. M.F.W. has nothing to disclose.

Funding Information:
The Coronary Artery Risk Development in Young Adults Study (CARDIA) is conducted and supported by the National Heart, Lung, and Blood Institute (NHLBI) in collaboration with the University of Alabama at Birmingham ( HHSN268201800005I & HHSN268201800007I ), Northwestern University ( HHSN268201800003I ), University of Minnesota ( HHSN268201800006I ), and Kaiser Foundation Research Institute ( HHSN268201800004I ). The CARDIA Women’s Study was supported by the NHLBI ( R01-HL-065611 ). AMH measurement was supported by an NHLBI Career Development Award (K23-HL-87114) and (R03-HL-135453). This manuscript has been reviewed by CARDIA for scientific content.

Publisher Copyright:
© 2020 American Society for Reproductive Medicine


  • Oxidative stress
  • ovarian reserve
  • ovary
  • reproductive age


Dive into the research topics of 'Antimüllerian hormone and F2-isoprostanes in the Coronary Artery Risk Development in Young Adults (CARDIA) Study'. Together they form a unique fingerprint.

Cite this